Clinical trials: Glial Tumors
Glioblastoma or Solid Tumors, Epidermal Growth Factor Receptor (EGFR) Diagnosis
Expanded Access to ABT-414
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to ABT-414 prior to approval by the local regulatory agency. Availability will depend on territory eligibility.
- Trial name
- NCT03123952
- Testing
- ABT-414
- Sponsor
- AbbVie
Advanced Glioma
CAR T Cells in Treating Patients With Malignant Gliomas Overexpressing EGFR
The purpose of this study is to determine whether autologous T cells bearing chimeric antigen receptor that can specifically recognize EGFR overexpressed in tumor cells is safe and effective for patients with EGFR-overexpressing…
- Trial name
- NCT02331693
- Testing
- anti-EGFR CAR T
- Where
- China
- Volunteers
- 10 people
- Sponsor
- RenJi Hospital
Low Grade Glioma of Brain, Anaplastic Glioma of Brain
Effects of Exercise on Cognitive Function in Glioma Patients
The objective of this pilot randomized controlled trial (RCT) is to assess the feasibility and to determine the effect size of an exercise program in improving objective cognitive functioning.
- Trial name
- NCT02303938
- Testing
- physical exercise
- Where
- Netherlands
- Volunteers
- 60 people
- Sponsor
- Tilburg University
Brain Neoplasms
Assessing Dynamic Magnetic Resonance (MR) Imaging in Patients With Recurrent High Grade Glioma Receiving Chemotherapy
The purpose of this study is to learn more about imaging changes induced by a new therapeutic agent, bevacizumab with the standard steroid, dexamethasone in patients with high grade glioma.
- Trial name
- NCT00769093
- Testing
- Ferumoxytol
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- OHSU Knight Cancer Institute
Glioma, Postoperative Motor Deficit
Transcranial Magnetic Stimulation in the Rehabilitation of Postoperative Motor Dysfunction.
This study focused on glioma patients with postoperative motor deficits, especially for patients with supplementary motor area syndrome.
- Trial name
- ATM (NCT04706338)
- Testing
- TMS treatment
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Neurosurgical Institute
Glioblastoma Multiforme (GBM) WHO Grade IV
Prospective Phase 2 Trial of Cabazitaxel in Patients With Temozolomide Refractory Glioblastoma Multiforme
The proposed study is an open-label, single-arm, Phase- II trial to assess the efficacy of cabazitaxel in GBM WHO grade IV patients with a progression during or within 6 months after last temozolomide treatment (Figure 1).
- Trial name
- NCT01866449
- Testing
- Cabazitaxel
- Where
- 3 sites in Germany
- Volunteers
- 24 people
- Sponsor
- University of Ulm
Glioblastoma Multiforme, Gliosarcoma
Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma
The primary objective of this study is to determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of dasatinib when combined with protracted, daily temozolomide (TMZ).
- Conditions
- Glioblastoma Multiforme, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
- Trial name
- NCT00734864
- Testing
- enzyme-inducing anti-epileptic drugs
- Where
- United States
- Sponsor
- Annick Desjardins
Glioma, Diffuse Astrocytoma, IDH-Wildtype (Grade 2-4)
A Study of 177Lu-PSMA-617 in People With Gliomas
The researchers are doing this study to find out whether the radiopharmaceutical therapy (RPT) 177Lu-PSMA-617 is a safe treatment for people with IDH wild type glioma.
- Conditions
- Glioma, Diffuse Astrocytoma, IDH-Wildtype (Grade 2-4), Glioblastoma, IDH-wildtype, Diffuse Midline Glioma, H3 K27-Altered
- Trial name
- NCT07223034
- Testing
- Temozolomide, 177Lu-PSMA-617, 68Ga-PSMA-PET scan/ MRI
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Glioma
Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade Gliomas
The objective of this expanded access program is to provide ONC201 to eligible patients with previously-treated glioma that exhibits the H3 K27M mutation and/or that is located in the midline region of the brain.
- Trial name
- NCT03134131
- Testing
- ONC201
- Where
- United States
- Sponsor
- Jazz Pharmaceuticals
Brain and Central Nervous System Tumors
Carmustine in Treating Patients With Recurrent Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of carmustine in treating patients who are undergoing…
- Trial name
- NCT00004028
- Testing
- carmustine, conventional surgery
- Where
- 9 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Brest Cancer, Lung Cancer (NSCLC)
The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling
The purpose of the CCANED-CIPHER study is to develop and validate an AI-based blood test for early cancer detection and to monitor treatment effectiveness in cancer patients.
- Conditions
- Brest Cancer, Lung Cancer (NSCLC), Pancreatic Cancer, Adult, Prostate Cancers
- Trial name
- CCANED-CIPHER (NCT06717295)
- Testing
- DiNanoQ: A multi-cancer early detection (MCED) blood test, DiNanoTrack: Therapeutic Response Monitoring Blood Test
- Where
- 4 sites in Argentina, Nigeria and 1 more
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Javier Toledo
Glioblastoma
PTK787/ZK 222584 in Combination With Temozolomide and Radiation in Patients With Glioblastoma Taking Enzyme-Inducing Anti-Epileptic Drugs
PTK is an investigational new drug that has been shown in early laboratory studies to prevent the formation of new blood vessels that allow the tumor to grow.
- Trial name
- NCT00385853
- Testing
- PTK787/ZK 222584, Temozolomide, Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Massachusetts General Hospital
Glioma, Neurofibromatosis Type 1
MicroRNAs in Patients With Neurofibromatosis Type 1
MicroRNAs are small molecules which have recently been discovered in cells. They are known to be responsible for the normal development of cells and when they are disrupted can contribute to the development of cancer.
- Trial name
- NCT01595139
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
Brain and Central Nervous System Tumors, Lymphoma
Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma
Phase II trial to study the effectiveness of rebeccamycin analogue in treating children who have solid tumors or non-Hodgkin's lymphoma.
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Neuroblastoma, Retinoblastoma
- Trial name
- NCT00006102
- Testing
- becatecarin
- Where
- 226 sites in United States, Australia and 5 more
- Volunteers
- 200 people
- Sponsor
- National Cancer Institute (NCI)
Newly-diagnosed Glioblastoma
Phase 2 Study of CAN008 in Subjects With GBM
This is a multi-center, randomized, double-blind, placebo-controlled Phase 2 study whose objectives are to evaluate the clinical efficacy and safety of CAN008 plus TMZ during and after radiation therapy in newly-diagnosed…
- Trial name
- NCT05447195
- Testing
- CAN008
- Where
- China
- Volunteers
- 117 people
- Sponsor
- CANbridge Life Sciences Ltd.
Glioma, Brain Neoplasm
EEG-Guided Cognitive Function Preservation in Patients With Brain Tumors
Brain tumors and their surgical treatment may impair cognitive function, affecting patients' quality of life. This prospective single-arm study aims to evaluate the feasibility and clinical utility of an EEG-based neural signal…
- Conditions
- Glioma, Brain Neoplasm, Brain Tumor Adult
- Trial name
- NCT07699172
- Testing
- EEG-Based Neural Signal Decoding Strategy
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Bo Wang
Low Grade Glioma, Neurofibromatosis Type 1
A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
This phase III trial studies if selumetinib works just as well as the standard treatment with carboplatin/vincristine (CV) for subjects with NF1-associated low grade glioma (LGG), and to see if selumetinib is better than CV in…
- Conditions
- Low Grade Glioma, Neurofibromatosis Type 1, Visual Pathway Glioma
- Trial name
- NCT03871257
- Testing
- Carboplatin, Magnetic Resonance Imaging, Quality-of-Life Assessment
- Where
- 132 sites in United States, Canada and 1 more
- Volunteers
- 165 people
- Sponsor
- National Cancer Institute (NCI)
IDH1-mutant Glioma, IDH2-mutant Glioma
Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma
The objective of this study is to determine the safety and tolerability of vorasidenib in combination with temozolomide (TMZ) and to establish the recommended combination dose (RCD) of vorasidenib.
- Trial name
- NCT06478212
- Testing
- Vorasidenib, Temozolomide (TMZ)
- Where
- 28 sites in United States, Austria and 9 more
- Volunteers
- 51 people
- Sponsor
- Institut de Recherches Internationales Servier
Low-grade Glioma, Temozolomide
Trial in Low Grade Glioma Patients: Wait or Treat
The 1635-EORTC-BTG study - Wait or Treat - concerns patients that represent a clinically favorable group of patients with IDHmutated astrocytoma (oligo-symptomatic), without a need for immediate post-operative treatment.
- Conditions
- Low-grade Glioma, Temozolomide, Phase III, Wait or Treat
- Trial name
- IWOT (NCT03763422)
- Testing
- Temozolomide, Radiotherapy, Surgery
- Where
- 45 sites in Australia, Austria and 8 more
- Volunteers
- 19 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Grade IV Malignant Glioma
Pilot Study of Bone Marrow/Stem Cells in Grade IV Malignant Glioma
1. Purpose of the Study - This protocol aims to demonstrate the feasibility and safety of autologous ALD-451 cells administered intravenously in World Health Organization (WHO) grade IV malignant glioma patients following…
- Trial name
- NCT01639612
- Testing
- ALD-451
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Henry Friedman
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.